2024-513958-29-00Active, not recruitingPhase 3
Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 21 Jul 2026
Brief summary (registry, in English)
To assess the feasibility of conducting a trial to determine whether targeting obesity with semaglutide in patients with resistant hypertension improves blood pressure control versus placebo.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 1 Oct 2024
- Start date
- 24 Apr 2025
- Lead sponsor
- Trinity College Dublin
- Diseases
- Obesity
- EU CT number
- 2024-513958-29-00
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 50
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with any GLP-1 RA or any medication for the indication of obesity within the past 90 days before screening.
- Previous surgery for weight reduction or major gastro-intestinal tract surgery
Other illness
- Presence or history of chronic pancreatitis or pancreatic cancer.
- Hypersensitivity to semaglutide, another GLP1-RA, or excipients of Ozempic®/Wegovy®.
- Personal/family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome
Lab values
- Comorbidities: Diabetes with a HbA1c ≥53mmol/L or a requirement for insulin treatment or diabetic retinopathy, previous pancreatitis/pancreatic cancer, end stage renal disease (eGFR <15ml/min), congestive heart failure NYHA class IV, limited life expectancy.
- Patients with severe renal impairment (eGFR < 30 ml/min1.73m2) including patients with end-stage renal disease, patients with severe hepatic impairment, congestive heart failure NYHA class IV, limited life expectancy.
- Diabetes with a HbA1c ≥53mmol/L or a requirement for insulin treatment or diabetic retinopathy.
Other
- Otherwise considered unsuitable by the principal investigator or their primary doctor.
- An episode of acute pancreatitis within the last 180 days.
- Female who is pregnant, breastfeeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method.
Who the study is looking for
- Obesity defined as a BMI ≥ 30kg/m2
- Resistant hypertension defined as: o Mean home systolic BP ≥ 130 mmHg measured in duplicate at a minimum of 6 timepoints. o Prescribed three or more anti-hypertensive medications, which should include a diuretic.
- Prescribed three or more anti-hypertensive medications at optimal doses, one of which should include a diuretic.
- Written informed consent to partake and availability for trial duration.
- Adults, aged ≥18 years at the time of signing informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centric Health Navan Road | Dublin | Ireland | Active, not recruiting |
| St James's Hospital | Dublin 8 | Ireland | Active, not recruiting |
| University Hospital Galway | Galway | Ireland | Active, not recruiting |
| TURLOUGHMORE MEDICAL CENTRE | Galway | Ireland | Active, not recruiting |
| Griffin Daly Medical Centre | Limerick | Ireland | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.